Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 4/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 5/20 | 0.39 |
| ▸ | NOS1 | P29475 | 5/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16668617 | 0.82 | SRC (0.44) | FGFR4SRC | |
| SCHEMBL16668592 | 0.80 | CYP11B1 (0.39) | — | |
| SCHEMBL16668845 | 0.80 | KDM4E (0.43) | SRCNOS3NOS1NOS2 | |
| SCHEMBL16667846 | 0.78 | FGFR4 (0.40) | FGFR4 | |
| SCHEMBL25384701 | 0.78 | KDM4E (0.49) | FGFR4ROCK2NOS3NOS1MAOB | |
| SCHEMBL16668884 | 0.76 | KDM4E (0.49) | SRC | |
| SCHEMBL16668543 | 0.76 | AAK1 (0.46) | — | |
| SCHEMBL6052479 | 0.75 | KDM4E (0.57) | ROCK2NOS3NOS1NOS2 | |
| SCHEMBL29458221 | 0.73 | ADORA2A (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL25384842 | 0.73 | ADORA2A (0.40) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | LEUKOS BIOTECH, S.L. (ES) | 2026-02-03 | — | — | US | disclosed |
| EP-4445901-A2 | NEW POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | Leukos Biotech, S.L. (ES) | 2024-10-16 | — | — | EP | disclosed |
| EP-4225753-B1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2024-07-31 | — | — | EP | disclosed |
| US-20240166639-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH, S.L. (ES) | 2024-05-23 | — | — | US | disclosed |
| CN-116635390-A | Potent and selective compounds as serotonin 1B receptor modulators | 莱科斯生物技术公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-4225753-A1 | POTENT AND SELCTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | Leukos Biotech, S.L. (ES) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022074103-A1 | POTENT AND SELCTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH, S.L. (ES) | 2022-04-14 | — | — | WO | disclosed |
| EP-3060563-B1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9896449-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-03-09 | — | — | US | disclosed |
| US-9533988-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-01-03 | — | — | US | disclosed |
| EP-3060563-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| US-9266883-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| WO-2015059668-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2015-04-30 | — | — | WO | disclosed |
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR3B, HTR1B, HTR1A | FGFR4 3893/4885ROCK2 3058/4885SRC 2591/4885 |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | HTR3B, HTR1A, HTR1B | FGFR4 3851/4885ROCK2 2270/4885SRC 2064/4885 |
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885ROCK2 844/4885SRC 87/4885 |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885ROCK2 844/4885SRC 87/4885 |
| US-20240166639-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR1B, HTR1A, HTR3B | FGFR4 3241/4885ROCK2 2587/4885SRC 2931/4885 |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885ROCK2 844/4885SRC 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.